On June 17-18, 2021, the 'Improved New Drug Trend and Technology Conference' will be held at the Westin Hotel in Chongqing Jiefangbei. This summit is hosted by the Pharmaceutical Industry Circle. More than 50 experts are invited to learn from the experience of improved new drugs. , Technology, market and trends to share. Dr. Chen Yongqi, the chairman of our company, gave a report on the theme of 'Improved New Drug EU/U.S. Registration Application Experience Sharing-Taking Inhaled Preparations as an Example'. The conference attracted nearly a hundred pharmaceutical companies, research institutes and universities to participate, and the summit was grand in scale.
Looking back on the 21st century, innovation has fallen into the pharmaceutical industry like a seed. In the first decade, the germination of innovation began. In the second decade, with the 4 trillion stimulus and the explosive emergence of biotechnology, biotechnology companies with original innovations sprung up like mushrooms after a rain, and to a certain extent affected the environment. Favor the direction of innovation. The atmosphere of innovation is getting better, but for the vast majority of generic drug companies in China, the threshold for innovation at the source is relatively high. The innovation vent in the next ten years will be the vent to solve the transformation problems of many generic pharmaceutical companies in China. For different pharmaceutical companies, innovation should not be a 'storm-like revolution', but a way out for survival based on the actual situation.
Dr. Chen Yongqi reported on the development of new crown inhalation preparations, the development strategy of inhalation preparations, and the reporting strategy of inhalation preparations. Include the following.
Recently, Israel has developed the anti-coronavirus inhalation preparation EXO-CD24, which has attracted widespread attention in the industry. The exosomal biological preparation can regulate inflammation and inhibit cytokine storm. This inhalation preparation directly delivered to the lungs can reduce the dosage and reduce the risk. Exosomes have high compatibility with the human body, so they have great advantages. Russia has also developed similar inhalation preparations. For lung diseases, the development of aerosol inhalation preparations is an idea of drug improvement, avoiding the first pass effect of the liver, rapid response to the therapeutic effect, and reducing risks. At the same time, inhaled preparations have R&D barriers, approval barriers and production barriers, and the market potential is also very large. In addition, the path of drug improvement can also be started by improving the dosage form, such as oral microsphere preparations, injection preparations, long-acting preparations, sustained-release preparations, etc. It can also be done by changing the route of administration, new formulations, and new indications.
Improved new drugs are hailed as the outlet for the next ten years. Its R&D difficulty is between the original innovative drugs and general generic drugs. Most of the projects can bring huge returns to pharmaceutical companies while reducing risks and investment.